Golimumab for the treatment of Psoriatic Arthritis

17th March 2011

British Society for Rheumatology (BSR) welcomes the guidance from National Institute for Health and Clinical Excellence (NICE) on the use of Golimumab for patients with psoriatic arthritis.

Dr Ian Rowe, Chair of BSR Clinical Affairs Committee said; "We are very pleased that NICE has given positive guidance on the use of Golimumab for patients with psoriatic arthritis.  This offers patients with psoriatic arthritis the opportunity to get this new treatment and the benefits that it may bring.  We hope that NICE will also respond positively to the appraisals for the use of this medicine for other indications, so that patients with rheumatoid arthritis can also get the benefits that this medicine might give them."

For further details contact Debbie Smith